PDCD1 and Miyoshi myopathy: To date, immunotherapies targeting immune checkpoints in MM, such as PD-1, have had limited clinical efficacy and the combination of αPD-1 with IMiDs in phase III clinical trials (KEYNOTE-183 and KEYNOTE-185) was associated with decreased overall survival (3, 9, 10, 26).